NEWPORT NEWS, Va., June 2, 2025 /PRNewswire/ — Dilon Technologies is pleased to announce the partnership of Australian Allografts as the exclusive distributor of the Navigator 2.0™ Lymphatic Mapping System in Australia, effective immediately.

This strategic collaboration reflects Dilon Technologies’ ongoing commitment to delivering exceptional patient care through advanced medical technology. By partnering with Australian Allografts and their specialized support team, Dilon is enhancing access to the Navigator 2.0 system and reinforcing their ability to provide localized, responsive service throughout the region.

"Dilon Technologies remains steadfast in its mission to improve patient outcomes by equipping healthcare providers with precise, reliable, and user-friendly technology. The Navigator 2.0 Gamma Localization System is a critical component in breast surgery, and ensuring its continued availability is central to our dedication to clinicians and the patients they serve," stated George Makhoul, CEO of Dilon Technologies.

In addition to the Navigator 2.0 system, Australian Allografts will also support the full portfolio of Dilon products, upholding the high standards of quality, performance, and support that healthcare providers and their patients rely on.

Logo – https://mma.prnasia.com/media2/1916512/Dilon_Technologies_Logo.jpg?p=medium600

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Gravitas Education Holdings, Inc. Announces Expected Timing for the Effective Time of the Merger

BEIJING, Dec. 12, 2023 /PRNewswire/ — Gravitas Education Holdings, Inc. (the "Company")…

SIAL Shanghai 2025: Own Asia's Changing Food Market and Inspire New Business with the Tutto Pizza Initiative

BEIJING, Feb. 10, 2025 /PRNewswire/ — As China’s dynamic food and beverage…

China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA

BEIJING, June 1, 2026 /PRNewswire/ — Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class…